{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endocrine%2FNeuroendocrine", "query": { "condition": "Endocrine/Neuroendocrine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 452, "total_pages": 46, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endocrine%2FNeuroendocrine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T12:15:39.979Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04459273", "title": "Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Carcinoma", "Cervical Carcinoma", "Cholangiocarcinoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Hepatocellular Carcinoma", "Malignant Adrenal Gland Neoplasm", "Malignant Brain Neoplasm", "Malignant Pleural Neoplasm", "Malignant Skin Neoplasm", "Malignant Solid Neoplasm", "Malignant Testicular Neoplasm", "Malignant Thymus Neoplasm", "Neuroendocrine Neoplasm", "Thyroid Gland Carcinoma", "Urothelial Carcinoma", "Cancer of Unknown Primary Site" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gallium Ga 68 FAPi-46", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "18F-FDG", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2020-08-27", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-07-22T12:15:39.979Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04459273" }, { "nct_id": "NCT00869050", "title": "Capecitabine and Temozolomide for Neuroendocrine Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 41, "start_date": "2005-08", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2016-07-25", "last_synced_at": "2026-07-22T12:15:39.979Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00869050" }, { "nct_id": "NCT05746182", "title": "Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Neuroendocrine Neoplasm" ], "interventions": [ { "name": "Hereditary Cancer Panel", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2023-04-07", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-07-22T12:15:39.979Z", "location_count": 3, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05746182" }, { "nct_id": "NCT02452424", "title": "A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Gastrointestinal Stromal Tumor (GIST)", "Ovarian Cancer" ], "interventions": [ { "name": "PLX3397", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2015-07-02", "completion_date": "2018-10-12", "has_results": true, "last_update_posted_date": "2020-03-05", "last_synced_at": "2026-07-22T12:15:39.979Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02452424" }, { "nct_id": "NCT00084461", "title": "Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrinoma", "Glucagonoma", "Insulinoma", "Metastatic Gastrointestinal Carcinoid Tumor", "Pancreatic Polypeptide Tumor", "Pulmonary Carcinoid Tumor", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Regional Gastrointestinal Carcinoid Tumor", "Somatostatinoma" ], "interventions": [ { "name": "romidepsin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2004-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-07-22T12:15:39.979Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00084461" }, { "nct_id": "NCT01528774", "title": "Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Blood Draw", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wolfram Samlowski", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2016-06", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-07-22T12:15:39.979Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT01528774" }, { "nct_id": "NCT02650986", "title": "Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Fallopian Tube Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Ovarian Carcinoma", "Advanced Primary Peritoneal Carcinoma", "Advanced Synovial Sarcoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Fallopian Tube Carcinoma", "Metastatic Melanoma", "Metastatic Ovarian Carcinoma", "Metastatic Primary Peritoneal Carcinoma", "Metastatic Synovial Sarcoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Primary Peritoneal Cancer AJCC v8", "Stage IIIA Fallopian Tube Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Primary Peritoneal Cancer AJCC v8", "Stage IIIA1 Fallopian Tube Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Fallopian Tube Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Fallopian Tube Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Primary Peritoneal Cancer AJCC v8", "Stage IIIC Fallopian Tube Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Primary Peritoneal Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8", "Stage IVA Fallopian Tube Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Primary Peritoneal Cancer AJCC v8", "Stage IVB Fallopian Tube Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Primary Peritoneal Cancer AJCC v8", "Unresectable Melanoma", "Unresectable Ovarian Carcinoma", "Unresectable Synovial Sarcoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 15, "start_date": "2017-07-14", "completion_date": "2032-07-14", "has_results": true, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-07-22T12:15:39.979Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02650986" }, { "nct_id": "NCT03686124", "title": "ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Cancer", "Recurrent Cancer", "Solid Tumor, Adult", "Cancer" ], "interventions": [ { "name": "IMA203 Product", "type": "BIOLOGICAL" }, { "name": "IMA203 product- flat dose", "type": "BIOLOGICAL" }, { "name": "IMA203CD8 Product", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "IMADetect®", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "Immatics US, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 375, "start_date": "2019-05-14", "completion_date": "2032-06", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-07-22T12:15:39.979Z", "location_count": 13, "location_summary": "Stanford, California • Aurora, Colorado • Miami, Florida + 8 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03686124" }, { "nct_id": "NCT02611024", "title": "Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Glioblastoma", "Soft Tissue Sarcoma (Excluding GIST)", "Endometrial Carcinoma", "Epithelial Ovarian Carcinoma", "Mesothelioma", "Gastroenteropancreatic Neuroendocrine Tumor", "SCLC", "Gastric Carcinoma", "Pancreatic Adenocarcinoma", "Colorectal Carcinoma", "Neuroendocrine Tumors" ], "interventions": [ { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2016-05-06", "completion_date": "2025-07-01", "has_results": false, "last_update_posted_date": "2025-07-09", "last_synced_at": "2026-07-22T12:15:39.979Z", "location_count": 4, "location_summary": "Santa Monica, California • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02611024" }, { "nct_id": "NCT04116320", "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Breast Cancer", "Merkel Cell Carcinoma", "Squamous Cell Cancer", "Non Small Cell Lung Cancer", "Cervical Cancer", "Urothelial Carcinoma", "Ovarian Cancer", "Hepatocellular Carcinoma", "Small-cell Lung Cancer", "Microsatellite Instability High", "Gastric Cancer", "Esophageal Cancer" ], "interventions": [ { "name": "Echopulse", "type": "DEVICE" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Standard of Care PD-1 Therapy", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2019-11-21", "completion_date": "2023-08-15", "has_results": false, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-07-22T12:15:39.979Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04116320" } ] }